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Abstract 
Background: A drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe T cell mediated hyper-
sensitivity reaction. Relapses of symptoms in the recovery phase are frequent and linked to the reduction of the corti-
costeroid treatment, to viral reactivations or to the exposure to new drugs. Here, we analyzed, how often the exposure 
to new drugs leads to new sensitization or drug-related relapses without detectable sensitization.
Methods: 46 patients with DRESS treated in the allergy division of the Inselspital, Bern University Hospital, were ret-
rospectively assessed. Drug-related relapses were analyzed in terms of frequency and whether a possible sensitization 
evaluated by skin tests and/or lymphocyte transformation tests (LTT) to the new drugs was detectable. Furthermore, 
drug tolerance was evaluated in a subset of patients.
Results: 56 relapses were observed in 27 of 46 patients with DRESS (58.7%). 33 (58.9%) of these relapses were associ-
ated with the use of new drugs, 30 drug-related relapses were evaluated by patch test and/or lymphocyte transfor-
mation test. In 8/30 (26.7%) drug-related relapses, a sensitization to the new drug was demonstrated, suggesting the 
emergence of a multiple drug hypersensitivity syndrome (MDH). 14 patients experienced 22 drug-related relapses 
without any detectable sensitization and only 1/6 patients developed new symptoms upon reexposure.
Conclusion: Patients with DRESS frequently suffered from drug related relapses. Half of the patients with drug-
related relapses developed a MDH with proven sensitizations not only to the DRESS inducing drugs, but also to newly 
applied drugs. When not sensitized, drugs involved in drug related relapses could be reintroduced, if needed. Here, 
we propose a procedure for drug testing and future management of drug-related relapses in DRESS.
Keywords: Drug hypersensitivity, Drug allergy, Multiple drug hypersensitivity syndrome (MDH), Flare-up reaction, 
Relapse, Drug reaction with eosinophilia and systemic symptoms (DRESS), T-cell, Eosinophilia, Drug induced 
hypersensitivity syndrome (DiHS)
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Introduction
Drug reactions with eosinophilia and systemic symptoms 
(DRESS), also called drug induced hypersensitivity syn-
drome (DiHS) are severe T cell mediated drug hypersen-
sitivity reactions (DHRs), leading to exanthema, fever, 
eosinophilia, lymphadenopathy, and hepatitis [1–3]. 
Other organs such as the kidneys, heart, lungs, pancreas, 
bone marrow, or the cerebral areas are affected occa-
sionally [2, 3]. The clinical recognition of DRESS is chal-
lenging. Especially in the prodromal stage, non-specific 
symptoms resembling those of infections or autoim-
mune diseases may appear [4]. Furthermore, the latency 
period between exposure and symptoms is usually long 
(2–8  weeks) [5]; consequently drugs as potential trig-
gers are often not considered. However, shorter latency 
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periods (< 14  days) have been observed [6]. Despite 
discontinuation of the causing drug, clinical improve-
ment is often delayed [7]. DRESS may persist for weeks 
or sometimes even for months [8]. Relapses manifesting 
as exacerbations of exanthema, recurrent eosinophilia, 
or hepatitis are typical, even if the inducing drug is dis-
continued [4, 9]. Relapses may be related either to viral 
reactivations [7, 10], or to rapid reduction of systemic 
steroids [4, 11], or to administration of new drugs or to 
previously tolerated drugs after dose increase [4, 12–14].
Picard et al. find in their study that 25% of the DRESS 
patients had drug-related relapses [13]. However, they 
did not evaluate if these patients were sensitized to the 
causing drug. Drug-related relapses, for which sensitiza-
tion to the newly introduced drug has not been proven 
may be associated with an unknown mechanism such 
as stimulation of already activated T cells. In these cases 
patients may tolerate the suspected drug after complete 
recovery from the relapse. On the other hand, some 
patients showed a new T cell sensitization to the caus-
ing drug, leading to a multiple drug hypersensitivity 
syndrome (MDH) [14–16]. These patients are at risk of 
developing a drug hypersensitivity on re-exposure [17], 
therefore, they have to avoid multiple structurally dif-
ferent drugs. Thus, the distinction between drug-related 
relapse without proven sensitization and MDH is pivotal 
for the subsequent therapeutic management.
The aim of this study was to assess the frequency of 
drug-related relapses and to evaluate whether skin tests 
and/or lymphocyte transformation tests are useful in 
drug-related relapses to identify patients with MDH.
Methods
Study design
This study was a monocentric, retrospective analysis of 
patients with DRESS, examined between January 2011 
and December 2018 at the out-patient allergy division of 
the Inselspital, Bern University Hospital, Switzerland. All 
data were obtained in September 2019 using a search tool 
from the hospital record database. DHR cases listed as 
“DRESS”, “drug reaction with eosinophilia and systemic 
symptoms”, “drug rash with eosinophilia and systemic 
symptoms”, “drug induced hypersensitivity syndrome”, 
“DiHS” and the combined terms “hypersensitivity”, "exan-
thema", "eosinophilia" and "fever" were evaluated. All 
patients included in this study gave informed consent for 
study participation and data publication. The study was 
approved by the local ethics committee (Kantonale Ethik-
kommission Bern).
Study population
All DRESS cases were evaluated based on the Regiscar 
scoring system [18], which classifies a DRESS as definitive 
case (≥ 6 points), probable case (4–5 points), possible 
case (2–3 points) or no case (< 2 points). Only patients 
with a probable or definite DRESS with ≥ 4 points and 
a complete allergy workup (skin tests and/or lympho-
cyte transformation test (LTT) to involved drugs) were 
included. Skin tests and LTT were performed during the 
recovery state within 24 months after diagnosis DRESS. 
Skin test results were evaluated according to the EAACI/
ENDA guidelines [19]. Since intradermal tests carry the 
risk of triggering a relapse in DRESS, all skin tests were 
performed using patch tests [20]. Although patch tests 
may have a low risk of relapse, they are generally consid-
ered to be safe in severe DHR [20]. For drugs with limited 
information on non-irritant test concentrations, 10–30% 
dilutions in petrolatum were used for patch test accord-
ing to the guidelines of the European Society of Contact 
Dermatitis [21] (Additional file  1: Table  S1). Exclusion 
criteria for this study were pre-existing eosinophilic skin 
disorder, confirmation of another diagnosis, which could 
explain the DRESS like symptoms, incomplete cases, a 
refusal to participate, and missing follow up at our allergy 
division.
Patient assessment
For each DRESS case, the following information have 
been recorded and analyzed: clinical features (e.g. exan-
thema, fever, eosinophilia, presence of atypical lympho-
cytes, organ involvement), administered drugs, latency 
period, comorbidities, the occurrence of relapses in the 
course and after the DRESS period, and results of skin 
test and lymphocyte transformation test (LTT). All cases 
were assigned to either one of two groups:
Group 1: DRESS, without proven drug-
sensitization(s).
Group 2: DRESS with proven drug-sensitization(s) to 
inducing drug.
In each group the focus was on relapses occurring dur-
ing or within 24 months after resolution of DRESS. The 
frequency of drug-related relapses and skin tests and/or 
LTT to possibly involved drugs was investigated. Patients 
who were re-exposed to the triggering drug after the 
relapse resolution were identified. The detailed proce-
dure is summarized in a flowchart (Fig. 1).
MDH was defined as an immune mediated DHR to 
two or more unrelated drugs confirmed either by skin 
or by in-vitro tests [14, 15]. A relapse was defined as 
a transient re-occurrence of clinical symptoms and/or 
laboratory signs during or following the initial DHR 
(such as exanthema, recurrent eosinophilia, elevation 
of liver enzymes). All relapses were evaluated for a tem-
poral relationship to the administration of new drugs or 
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the reduction of systemic steroids. They were divided 
into three subgroups based on possible causes: (a) 
spontaneous forms without obvious cause; (b) relapses 
within two days after systemic steroid reduction; (c) 
relapses in connection with the administration of new 
drugs or dose increase of a previously tolerated drug 
(within three days). Viral re-activations were evaluated 
only in a minority of subjects and were not considered 
in this classification of relapses.
Statistical analysis
Analyses were performed using Graphpad Prism 8 
(GraphPad Software, Inc, La Jolla, CA, USA). All results 
were summarized using descriptive statistics. Propor-
tions were expressed in percentage; several continuous 
variables (eg. age, latency period etc.) were reported as 
mean and standard deviation or median and interquar-
tile ranges.
Results
Patient characteristics
87 patients with DRESS were identified in our data-
base (Fig.  1). 19 of these patients achieved a Regiscar 
score of less than 4 and were thus excluded. Most of 
these excluded cases had severe forms of maculopapu-
lar exanthema (MPE) with fever, eosinophilia, and facial 
swelling without organ involvement or a duration of 
DRESS ≤ 14  days. Five subjects were excluded due to 
incomplete data, nine could not be contacted or refused 
to participate. Six patients were excluded due to miss-
ing or incomplete allergy workup or follow-up, and two 
patients had a lethal outcome. 46 patients fulfilled all cri-
teria and were evaluated (Table  1). The most frequently 
Assessed for eligibility (n=87 ) Excluded (n=41)
Regiscar Score <4 (n=19)
Incomplete data (n=5)
Could not be contacted or 
refused to participate  (n=9)
Missing skin- or in vitro test, or 
no follow-ups (n=8, including 2 
cases with fatal outcome)
Included (n=46)
Proven sensitization to DRESS 
trigger in skin- or in vitro test to 
initial reaction?
yesno
Group 1: Cases (n=8)
Relapses: 12 in 6 cases
a.) Spontaneous: 3 in 3 cases
b.) After steroid reduction: 3 in 2 case
c.) Drug-related relapses: 6 in 5 cases
c.) Drug-related relapses: 6 in 5 cases
- Evaluated by skin- or in vitro test: 5 in 4 cases
- Proven sensitization to the trigger: 0
- Re-exposure: 0
- No sensitization: 5 in 4 cases
- Re-exposure: 2 in 2 cases (all tolerated)
Group 2: Cases (n=38, 25 DRESS without MDH, 13 
DRESS/MDH)
Relapses: 44 in 21 cases
a.) Spontaneous: 8 in 7 cases
b.) After steroid reduction: 9 in 6 cases
c.) Drug-related relapses: 27 in 13 cases
c.) Drug-related relapses: 27 in 13 cases
- Evaluated by skin- or in vitro test: 25 in 12 cases
- Proven sensitization to the trigger: 8 in 8 cases
- Re-exposure: 1 in 1 case (not tolerated)
- No sensitization: 17 in 10 cases
- Re-exposure: 5 in 4 cases (4 of 5 tolerated)
Fig. 1 Study procedure and patient allocation. DRESS cases were assigned to one of two groups: group 1: DRESS without proven drug sensitization 
and group 2: DRESS with proven drug sensitization to inducing drug. Frequency of drug-related relapses (subgroups a-c), skin tests and/or LTT 
to possibly involved drugs were evaluated in each group. Patients who were re-exposed to the triggering drug after the drug-related relapse 
resolution were identified
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involved organ was the liver (39/46, 84.8%), followed by 
the kidneys (12/46, 26.1%) and the bone marrow (cytope-
nia; 6/46, 13.0%). The mean peak eosinophilia level was 
3.0 G/L (± 3.5). Comorbidities were infectious (15/46, 
32.6%), cardiac (9/46, 19.6%), and autoimmune diseases 
(8/46, 17.4%). The median latency from the first drug 
intake to the occurrence of symptoms was 19 days (Range 
2–90  days). For 11/46 patients (23.9%), the latency was 
below 10 days.
Eight out of 46 patients (17.4%) were classified into 
group 1 without proven sensitization to a DRESS trigger: 
Seven out of eight patients were evaluated by skin test 
and LTT (one case without association to drugs). A caus-
ative drug inducing DRESS was identified in 38 patients 
(82.6%) (group 2) including 13 cases with DRESS/MDH 
(13/46, 28.1%). These 13 patients had been described 
earlier [14]. Of the 38 cases with proven sensitization, 
nine and five were evaluated only by skin test and LTT, 
respectively. In 24 patients both tests were performed, 
from which 13 had matching results. In six cases only the 
LTT and in two cases only the skin test revealed a sensi-
tization. Discrepant results were obtained in three cases 
(Additional file 1: Table S2).
Relapses in DRESS
In 27/46 (58.7%) patients with DRESS 56 relapses were 
observed. 12 occurred after systemic steroid reduc-
tion (21.4%) and 11 were spontaneous without an obvi-
ous cause (19.6%). Drug-related relapses occurred in 18 
patients (18/46, 39.1%) comprising 33 episodes (58.9%) 
(Fig.  2). Relapses were equally frequent in both groups 
(group 1: 50.0% of subjects; group 2: 55.3% of subjects). 
Drug-related relapses were observed more frequently in 
group 1 (5/8, 62.5% vs. 13/38 34.2%; p = 0.136).
An allergy workup with the drugs involved in the 
relapses was conducted in 16 patients (4 of subgroup 
1c and 12 of subgroup 2c) with 30 drug-related relapses 
(Fig.  1, Additional file  1: Table  S2). All drugs involved 
in relapses were different to the initial drugs causing 
DRESS. In eight patients from subgroup c, a sensitiza-
tion to a suspected and culprit drug was shown (8/16, 
50.0%): radio-/gadolinium based contrast agents (4), 
vancomycin (1), valproic acid (1), betalactam antibi-
otic (1), and a non-steroidal anti-inflammatory drug 
(NSAID) (1). No sensitization was found in the remain-
ing drug-related relapses (14 patients with 22/30 drug 
related relapses, 73.3%).
Subsequent tolerance of drugs that were involved 
in drug‑related relapses
Of the 14 patients of subgroup c with a drug-related 
relapse without proven sensitization, six subjects with 
seven corresponding relapses needed the suspected drug 
and were re-exposed: six re-exposures (two patients 
of subgroup 1c and four patients of subgroup 2c) were 
well tolerated: betalactam antibiotics (2), proton pump 
Table 1 Patient characteristics
Values are median and interquartile ranges (IQR) for continuous variables. 
Categorical variables reported as n (%)
Multiple drug hypersensitivity syndrome (MDH), drug reaction with eosinophilia 
and systemic symptoms (DRESS)
a Pancreatitis, gastrointestinal involvement, neurological involvement, myositis
b 2 cases with lethal DRESS outcome were excluded because of missing skin test 
and lymphocyte transformation test (see Fig. 1)
c Refers to the period of one month before the onset of DRESS: 5 × pneumonia, 
2 × acute prostatitis, 2 × endocarditis, 1 × septic arthritis, 1 × osteomyelitis, 
1 × acute cholecystitis, 1 × cellulitis, 1 × acute toxoplasmosis, 1 × acute 
rhinosinusitis
Total
N = 46
Demographics
 Age (at time of DRESS) 52.0 (38.3; 65.0)
 Gender (female) 23 (50.0%)
Clinical
 Exanthema (n) 46 (100.0%)
 Centro-facial oedema (n) 15 (32.6%)
 Fever > 38.0 ºC (n) 35 (76.1%)
 Eosinophilia > 0.5G/L (n) 40 (87.0%)
 Eosinophilia, mean (G/L) 3.0 ± 3.5
 Atypical lymphocytes (n) 20 (43.5%)
 Hepatitis (n) 39 (84.8%)
 Lymphadenopathy (n) 12 (26.1%)
 Renal involvement (n) 12 (26.1%)
 Pulmonary involvement (n) 2 (4.3%)
 Cardiac involvement (n) 2 (4.3%)
 Cytopenia (n) 6 (13.0%)
 Other organ  involvementa 7 (15.2%)
 Number of organs involved (mean) 1.4 ± 0.7
 Viral reactivation, detected in 8/13 (n) 8 (17.4%)
 Lethal outcome (n)b 0 (0.0%)
 DRESS with MDH 13 (28.1%)
Latency period (days) 19.0 (9.3; 27.8)
Comorbidities
 Autoimmune disease (n) 8 (17.4%)
 Renal insufficiency (n) 6 (13.0%)
 Infectious disease (n)c 15 (32.6%)
 Cardiac disease (n) 9 (19.6%)
 Epilepsy (n) 8 (17.4%)
 Neoplastic disease (n) 7 (15.2%)
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inhibitors (2), vancomycin (1) and paracetamol (1). In 
one patient (subgroup 2c; DRESS trigger: amoxicillin and 
ceftriaxon), the administration of vancomycin led to a 
generalized MPE after one day despite negative skin test 
(Additional file 1: Table S2).
One patient with a flucloxacillin-induced relapse (sub-
group 2c; DRESS trigger: carbamazepine) and a docu-
mented sensitization by skin test and LTT (sensitized 
to penicillins and cephalosporins) was accidentally re-
exposed to flucloxacillin, cefuroxime and ceftriaxon lead-
ing to a generalized MPE following each re-exposure 
(Additional file 1: Table S2).
Trigger of DRESS and drug related relapses
The most common drugs inducing DRESS with docu-
mented sensitization (not relapses) were penicillin 
antibiotics (especially piperacillin and amoxicillin; 
15/46, 32.6%), followed by aromatic anti-epileptics 
(9/46, 19.6%) and sulfonamides (6/46, 13.0%). Other 
triggers were cephalosporins, vancomycin and car-
bapenems (Fig.  3). Of the 11 patients with latency 
periods of ≤ 10 days, antibiotics were identified as trig-
ger in nine cases, from which seven were betalactam 
antibiotics.
Seven of the eight DRESS cases without proven sensi-
tization to a trigger (group 1) occurred after treatment 
with new drugs: in four cases, antibiotics were suspected 
to be the trigger: piperacillin/tazobactam (3), minocy-
cline (1).
Drugs involved in drug-related relapses were beta-lac-
tam antibiotics (8/33, 24.2%), vancomycin (4/33, 12.1%), 
radio- or gadolinium-based-contrast agents (5/33, 15.2%) 
and analgesics (4/33, 12.1%) (Additional file 1: Table S2).
Discussion
In more than half of our DRESS cases, a relapse was 
found. A drug-related relapse was observed in 39.1% 
of patients. The proportion of cases experiencing drug-
related relapses is higher than in the study of Picard 
et  al. [13], probably because we recorded also those 
relapses, occurring during active DRESS. The major-
ity of the relapses were related to new drugs. Only in 
a few cases, symptoms emerged spontaneously or after 
reduction of systemic steroids. How often viral re-acti-
vations were involved in relapses cannot be assessed 
based on our data, since this was only evaluated in 
13/46 patients.
There is one important question for the clinician: 
is it possible to administer drugs previously being 
involved in relapses again? 8/46 of our patients 
(17.4%) had drug-related relapses with proven sensi-
tization and were thus classified as MDH. Interest-
ingly, these patients were exclusively from group 2 
with a proven sensitization to a DRESS trigger. The 
total number of MDH cases was 13/46 (28.2%), from 
which three subjects did not develop drug-related 
relapses (Additional file  1: Table  S2). However, no 
sensitization to the involved drug was found in the 
majority of the drug-related relapses. In six out of 
seven skin test and/or LTT negative drug-related 
relapses, re-exposure to the triggering drug was well 
tolerated. Nevertheless, the limited sensitivity of 
the skin test and LTT needs to be taken into consid-
eration. Unfortunately, the underlying mechanism 
of skin test or LTT negative drug-related relapses 
remains unknown. Although a stimulation of already 
activated T cells may be assumed without persistent 
Number of patients, n=46
58.70%  DRESS with 1 or more relapses
41.30%  DRESS without relapses
Number of relapses, n=56
19.64%  Spontaneous relapse
21.43%  Relapse after systemic steroid reduction
58.93%  Drug-related relapses
Fig. 2 a Number of patients with flare-up reactions. b Form of flare-up reactions. A total of 56 relapses in 27 of 46 patients have been recorded. 
Drug reaction with eosinophilia and systemic symptoms (DRESS)
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sensitization [15], a missing causal relationship can-
not be excluded.
Although rarely mentioned in the literature [22–24], 
betalactam antibiotics, especially penicillin antibiotics 
such as amoxicillin and piperacillin were the most com-
mon triggers in our DRESS cases. Usually, high doses 
of penicillins are administered (up to 13.5 g/d!), which 
may promote the development of DHR and relapses 
[14, 15]. Interestingly, the administration of betalac-
tam antibiotics was associated with a relatively short 
latency (of < 10  days), an observation that was already 
described previously [6, 24].
The drugs involved in drug-related relapses are fre-
quently used in DRESS patients. Apart from beta-lac-
tam antibiotics, radio-contrast media, proton pump 
inhibitors, and analgesics have been relatively frequent 
involved in relapses.
Whether DRESS cases with and without proven sensi-
tization to the initial trigger are based on the same path-
omechanism is still unclear. If sensitization is proven, 
a drug-specific T cell reaction can be assumed. In case 
of a missing sensitization in skin test and/or LTT, a 
false negative test result is possible. However, another 
(unspecific) pathomechanism has to be considered. It 
is known that in particular penicillins can promote the 
re-activation of viruses [12] and are therefore capa-
ble of inducing a relapse. We found no significant dif-
ferences in the frequency of relapses between the two 
groups. However, there is a trend towards increased 
drug-related relapses in group 1 (patients without 
proven sensitization to a DRESS inducing drug). In con-
trast, a sensitization to drugs involved in relapses was 
only observed in group 2 (patients with a proven sen-
sitization to a DRESS inducing drug). Our data sug-
gest that drug-related relapses in DRESS cases without 
proven sensitization are unlikely to lead to a persistent 
sensitization.
Is reexposure reasonable in drug related relapses?
When evaluating drug allergy, not only the initial 
DRESS trigger should be considered, but also drugs 
that were administered during the active phase of 
DRESS, if involved in relapses. Santiago et  al. have 
recently shown that a large proportion of DRESS 
patients develop a new sensitization to antibiotics 
administered during DRESS [17]. Our data suggest that 
also other non-antibiotic drugs may cause relapses with 
detectable sensitization such as radio contrast agents, 
proton pump inhibitors and NSAID. We therefore 
propose the following procedure for drug testing and 
future management:
1. Verification of all potential drugs causing DRESS 
by skin test and/or LTT. In  vitro or patch tests 
(instead of intradermal test with late reading) should 
be performed to avoid the risk of relapses.
2. To discriminate between flare-up and MDH, all 
suspected drugs in subsequent relapses need to be 
tested, especially when administered temporarily 
during the active DRESS phase, e.g. radio contrast 
agents, NSAIDs, proton pump inhibitors and antibi-
otics.
3. In case of negative tests, reintroduction of these 
drugs may be allowed when needed, particularly in 
DRESS without proven sensitization. Proton pump 
inhibitors appear to be well tolerated. However, 
this approach bears a small risk of a relapse, which 
seems acceptable if index symptoms of the relapse 
were mild.
4. Alternatively, a preceding intradermal test and re-
exposure by graded challenge under clinical control 
can be considered. However, these patients who have 
just experienced a severe DHR, are understandably 
reluctant to challenge tests just for diagnosis.
The retrospective design and the fact that not all drug-
related relapses were tested are obvious limitations of 
the study. Re-exposures in test negative relapses were 
performed in only six patients (seven relapses). Further-
more, a selection bias could play a role. Since our data 
are mainly based on skin tests and LTT, false positive and 
false negative results are possible. However, especially the 
LTT is considered an adequate diagnostic tool for drug 
causality in DRESS [25].
Our observations need to be investigated in a larger, 
prospective study: all triggers that are involved in drug-
related relapses, especially antibiotics, should be system-
atically tested by skin test and LTT in consideration of a 
re-exposure in case of a negative result.
Conclusion
Patients with DRESS are at risk that new drugs may 
result in another severe DHR. It is therefore imperative 
to better understand and possibly avoid a MDH course. 
Our data show that drug-related relapses and MDH 
were common complications in DRESS. Most drug-
related relapses were not linked to a detectable immune 
response. Involved drugs can be administered again, 
when not sensitized. To avoid development of a MDH, it 
is advisable to be as restrictive as possible with adminis-
tration of new drugs during a DRESS reaction. All drugs 
involved in relapses should be tested, even when applied 
later in the DRESS course.
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